×
| Stock | Total Income | Net Profit | Net Sales | EPS | Market Cap (in Cr) | P/E |
|---|---|---|---|---|---|---|
| Shyama Computronics and Servic | 0.70 | 0.19 | 0.61 | NA | 4.02 | 30.9 |
| Triochem Products Ltd., | 4.59 | 0.88 | NA | 3.60 | 0 | |
| Alkem Laboratories Limited | 34672.7 | 6407.9 | 33742.8 | 52.34 | 54,933 | 25.4 |
| FORTIS HEALTHCARE LTD. | 19491.5 | 2543 | 19282.6 | 3.28 | 46785 | 59.5 |
| GLAXOSMITHKLINE PHARMACEUTICAL | 9814.2 | 2285.8 | 9463.6 | 13.49 | 42493 | 49.8 |
Alkem Laboratories Limited, with Security Code 539523, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.
| Metrics | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,058.3 | 2,461.4 | 2,296.7 | 2,237.9 | 2,253.1 | 2,634.5 | 2,494.5 | 2,365.3 | 2,500.1 | 2,871.9 |
| Expenses | 1,875.0 | 2,055.8 | 1,840.8 | 1,906.0 | 1,919.4 | 1,980.0 | 1,925.3 | 1,957.9 | 1,879.5 | 2,144.3 |
| Operating Profit | 183.3 | 405.7 | 456.0 | 332.0 | 333.8 | 654.6 | 569.3 | 407.5 | 620.6 | 727.6 |
| OPM % | 8.91% | 16.48% | 19.85% | 14.83% | 14.81% | 24.85% | 22.82% | 17.23% | 24.82% | 25.34% |
| Other Income | 55.3 | 73.6 | 60.7 | 76.6 | 64.7 | 61.8 | 44.4 | 71.3 | 106.1 | 120.2 |
| Interest | 22.0 | 20.0 | 22.6 | 21.7 | 21.4 | 18.7 | 21.1 | 20.7 | 21.4 | 17.6 |
| Depreciation | 56.8 | 57.7 | 58.1 | 57.2 | 58.1 | 59.0 | 58.1 | 69.1 | 64.4 | 62.6 |
| Profit before tax | 159.8 | 401.6 | 436.0 | 329.7 | 318.9 | 638.7 | 585.7 | 401.5 | 640.9 | 767.7 |
| Tax % | 12.3% | 12.7% | 10.8% | 22.7% | 14.9% | 1.2% | 5.6% | 16.5% | 9% | 9.1% |
| Net Profit | 140.1 | 350.7 | 388.9 | 254.8 | 271.4 | 646.5 | 504.2 | 325.0 | 583.3 | 697.6 |
| EPS in Rs | 11.72 | 29.33 | 32.53 | 21.31 | 22.7 | 54.07 | 42.17 | 27.18 | 48.78 | 58.34 |
| Metrics | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,079.4 | 3,040.9 | 2,902.6 | 2,967.7 | 3,440.2 | 3,323.9 | 2,935.8 | 3,031.8 | 3,414.7 | 3,374.3 |
| Expenses | 2,625.5 | 2,441.9 | 2,549.4 | 2,578.5 | 2,693.4 | 2,616.3 | 2,533.8 | 2,423.2 | 2,661.8 | 2,614.9 |
| Operating Profit | 453.9 | 599.1 | 353.3 | 389.2 | 746.7 | 707.6 | 402.0 | 608.6 | 752.8 | 759.4 |
| OPM % | 14.7% | 19.7% | 12.2% | 13.1% | 21.7% | 21.3% | 13.7% | 20.1% | 22% | 22.5% |
| Other Income | 50.7 | 45.3 | -34.3 | 65.8 | 5.5 | 42.3 | 75.7 | 120.3 | 134.5 | 93.0 |
| Interest | 24.9 | 27.1 | 29.0 | 29.8 | 30.3 | 25.5 | 26.9 | 29.1 | 28.1 | 36.0 |
| Depreciation | 77.4 | 78.4 | 78.3 | 72.4 | 73.9 | 69.6 | 83.4 | 80.5 | 78.9 | 85.3 |
| Profit before tax | 402.3 | 538.9 | 314.6 | 352.9 | 705.7 | 706.2 | 379.9 | 619.4 | 780.3 | 731.1 |
| Tax % | 13.6% | 14.6% | 68% | 18.4% | 5.1% | 7.7% | 17.1% | 11.2% | 10% | 12.3% |
| Net Profit | 347.7 | 460.0 | 67.7 | 287.8 | 614.9 | 604.3 | 304.5 | 550.2 | 702.0 | 640.8 |
| EPS in Rs | 27 | 38 | 5 | 23 | 51 | 49 | 24 | 45 | 57 | 52 |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 14% |
| 5 Years: | 11% |
| 3 Years: | 11% |
| TTM: | 4% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 18% |
| 3 Years: | 3% |
| TTM: | 34% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 12% |
| 3 Years: | 13% |
| 1 Year: | -13% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | 11% |
| 3 Years: | 13% |
| TTM: | 1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 20% |
| 3 Years: | 7% |
| TTM: | 29% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 12% |
| 3 Years: | 13% |
| 1 Year: | -13% |
Recent Bets
|
Date
|
Stock
|
Party
|
Deal
|
Trans.
|
Quan.
|
Price
|
Value
|
|---|